► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs<br /><br />Lex on whether 26% share climb is overly optimistic<br /><br />Shares in Eli Lilly had already risen 26% ahead of an announcement today about its hopes for its Alzheimer’s treatment. Lex's Richard Stovin-Bradford and Alan Livsey discuss whether the stock climb is overdone.<br /><br />► Lex: http://bit.ly/1I14JZF<br /><br />► FT Business: http://bit.ly/1KUK08s<br /><br /><br />For more video content from the Financial Times, visit http://www.FT.com/video<br /><br /><br />Twitter https://twitter.com/ftvideo<br />Facebook https://www.facebook.com/financialtimes
